Foresee Pharmaceuticals Co Ltd

Foresee Pharmaceuticals Co., Ltd. is a biopharmaceutical company operating in the United States, China, and Europe. Its stabilized injectable formulation pipeline includes FP-001, which completed a Phase III clinical study for advanced prostate cancer; FP-004, in preclinical stage for opioid use disorder; FP-011 and FP-014, long-acting sustained release forms for breast and prostate cancer; and FP-016 for neurological diseases. Its new chemical entity pipeline includes FP-020 for sarcoidosis, idiopathic pulmonary fibrosis, and pulmonary emphysema; FP-025, a selective matrix metalloproteinase-12 inhibitor in Phase II for asthma, chronic obstructive pulmonary disease, and acute respiratory distress syndrome in COVID-19 patients; FP-045, a selective aldehyde dehydrogenase (ALDH2) activator that completed Phase I for Fanconi anemia; and FP-040, an ALDH2 activator for central nervous system diseases. The company was incorporated in 2013 and is headquartered in Taipei, Taiwan.